PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
74.40%
Cash & equivalents growing 74.40% while AVXL's declined -99.39%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
74.40%
Below half of AVXL's -99.39%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
70.82%
Below half of AVXL's -99.39%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Below half of AVXL's -99.39%. Michael Burry sees a potential red flag for stagnation or capital shortage.
72.56%
Above 1.5x AVXL's 1.49%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-50.51%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.03%
Exceeding 1.5x AVXL's 0.78%. Michael Burry suspects ballooning short-term obligations vs. competitor.
36.12%
Above 1.5x AVXL's 0.78%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.12%
Above 1.5x AVXL's 0.78%. Michael Burry sees a potential leverage warning sign.
10.25%
Higher Common Stock (Book Value) Growth compared to AVXL's zero value, indicating worse performance.
-4.93%
≥ 1.5x AVXL's -0.28%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
247.64%
Below half AVXL's -3.19%. Michael Burry sees potential underperformance in building shareholder capital.
70.82%
Below half AVXL's -99.39%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-50.51%
Less than half of AVXL's 27.09%. David Dodd sees less overall debt expansion vs. competitor.
-77.35%
Less than half of AVXL's 46.53%. David Dodd sees better deleveraging or stronger cash buildup than competitor.